Skuteczność i opłacalność ekonomiczna chirurgii epilepsji u pacjentów z epilepsją oporną na leki: przegląd systematyczny modeli analizy decyzyjnej

PubMedNeurosurg Rev

Effectiveness and cost-effectiveness of epilepsy surgery in patients with refractory epilepsy: A systematic review of decision-analytic models

W skrócie

Badanie porównało chirurgię epilepsji z leczeniem farmakologicznym u pacjentów z epilepsją oporną na leki. Chirurgia okazała się bardziej skuteczna - u 37-64% pacjentów doprowadziła do całkowitego ustąpienia napadów, a u kolejnych 25-42% do ich znacznego zmniejszenia. Chociaż koszty operacji były wysokie, w wielu przypadkach operacja była opłacalna ekonomicznie, czasami nawet taniej niż długoterminowe leczenie lekami.

Oryginalny abstract (angielski)

Our objective was to evaluate the effectiveness and cost-effectiveness of epilepsy surgery for the treatment of patients with DRE. We carried out a systematic review of Decision Analytic Models (DAMs) in the main international databases regarding the comparison between epilepsy surgery versus medical treatment. We evaluated the relevance and credibility of the DAMs with the ISPOR-AMCP-NPC tool. We synthesized the results qualitatively. The certainty of the body of evidence was determined using the GRADE approach proposed for modeling studies. Clinical and economic outcomes were synthesized narratively because substantial heterogeneity existed across studies in epilepsy etiology, patient populations, model structures, perspectives, time horizons, and outcome definitions, precluding formal meta-analysis and quantitative pooling of cost-effectiveness estimates. Surgery was associated with higher reported rates of seizure freedom and seizure reduction than medical treatment, with seizure freedom ranging from 37.1% to 64.0% and seizure reduction from 24.6% to 42.2%. Reported QALY gains ranged from 0.3 to 3.0. Incremental costs varied substantially, ranging from savings of I$116,642 to additional costs of I$227,146 per patient. ICERs ranged from dominant (less costly and more effective) to I$291,091 per QALY gained. For seizure-related outcomes, ICERs ranged from I$454 to I$1,268 per 1% increase in seizure reduction and from I$5.83 to I$1,782 per 1% increase in seizure freedom, reflecting substantial variation in healthcare settings, perspectives, time horizons, and economic models. Epilepsy surgery is considered an effective and cost-effective option in patients with DRE, although the evidence is still low and very low certainty. So future studies of higher methodological quality are needed to better assess the picture and corroborate these results.Clinical trial number: Not applicable.

Metadane publikacji

Journal
Neurosurg Rev
Data publikacji
16.11.2026
PMID
43035593
DOI
10.1007/s10143-026-04554-w
Autorzy
Alva-Diaz C, Rimachi VAV, Grados-Espinoza P, Cabanillas-Lazo M, Terry F, Nieto W, Huerta-Rosario M, Quispe-Vicuña C, Pacheco-Barrios N, Enriquez-Marulanda A
Słowa kluczowe
Cost-effectiveness, Decision analytic models, Drug-resistant epilepsy, Effectiveness
Źródło
PubMed